epidermal growth factor receptor 2
The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study
... fibroblast growth factor receptor 2 (FGFR2), and human epidermal growth factor receptor 2 (HER2) in human GC and their clinical significance in clinical ...
11
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients
... human epidermal growth factor receptor 2 (HER2), phosphatase and tensin homolog (PTEN), and insulin-like growth factor 1 receptor ...
10
Prognostic significance of Human epidermal growth factor receptor 2 expression in patients with resectable gastric adenocarcinoma
... Human epidermal growth factor receptor 2 (HER2), a target used in breast cancer treatment, is the second member of the epidermal growth factor receptor ...
9
New developments in the treatment of HER2-positive breast cancer
... human epidermal growth factor receptor-2 (HER2) tyrosine ...of epidermal growth factor receptor and HER2 tyrosine kinases, and is approved for ...
12
Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
... Abstract: Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 ...
13
STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
... estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), represents the most aggressive and mortal subtype of breast ...
16
<p>Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date</p>
... an epidermal growth factor-receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) ...tropomyosin receptor kinase (NTRK) in all patients whose cancers express it (making it a ...
16
Triple-negative breast cancer: new perspectives for targeted therapies
... Abstract: Breast cancer is a heterogeneous disease, encompassing a large number of entities showing different morphological features and having clinical behaviors. It has became apparent that this diversity may be ...
17
The progress of targeted therapy in advanced gastric cancer
... Approximately one million people are diagnosed each year with gastric cancer, making it the fourth most com- mon cancer and the second leading cause of cancer re- lated death worldwide with an estimated 800,000 deaths ...
8
6100.pdf
... EGFR(epidermal growth factor receptor) and the related HER-2 (human epidermal growth factor receptor 2) associated with breast cancer has allowed for ...
46
Immunohistochemical profile and its association with clinicopathological parameters in carcinoma breast: a prospective study in central India
... (PR) receptor and Her-2/neu (human epidermal growth factor receptor type 2) analysis have been accepted as established procedures in routine management of the patients ...
7
Prognostic Implications of ER, PR and HER2/Neu Protein Expression in a Cohort of Breast Carcinoma
... HER 2/neu was positive in 25% of patients with distant metastasis and ...human epidermal growth factor receptor including the risk of brain ...predictive factor for response to ...
6
Prognostic value of <em>EGFR</em> and <em>KRAS</em> in resected non-small cell lung cancer: a systematic review and meta-analysis
... of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with ...mal growth factor receptor gene is not a prognostic factor for ...
12
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis
... the epidermal growth factor receptor ...Human epidermal growth factor receptor (HER)2 and EGFR have attracted much attention in the medical literature over ...
8
The autotaxin-lysophosphatidic acid–lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme
... Bevacizumab, a monoclonal antibody that recognizes VEGF, is currently clinically approved for GBM treat- ment. Unfortunately, although bevacizumab treatment prolongs progression-free survival in a subset of pa- tients, ...
9
Synthesis, characterization and molecular docking studies of anilinoquinazoline derivatives
... endothelial 2) and epidermal growth factor receptor (EGFR) inhibitors were 2 and EGFR and amongst them PR-6 has shown maximum ...inhibitor 2 and ...
9
HER2 therapy: Molecular mechanisms of trastuzumab resistance
... A potential mechanism by which resistance to targeted antibodies may develop is via disruption of the interaction between the therapeutic agent and the target protein. Resistance to trastuzumab was associated with ...
8
Mutations in the phosphatidylinositol 3 kinase pathway: role in tumor progression and therapeutic implications in breast cancer
... human epidermal growth factor receptor (HER)2 and other receptor tyrosine ...estrogen receptor (ER)+ breast cancer cells, PI3K activation promotes estrogen- dependent and ...
12
Growth factor regulation of proliferation and survival of multipotential stromal cells
... of growth and other trophic factors may be helpful in counteracting these twin issues of MSC expansion and ...death. Growth factors are known to infl uence cell proliferation, motility, survival and ...the ...
12
v rasH induces non small cell phenotype, with associated growth factors and receptors, in a small cell lung cancer cell line
... and growth characteristics consistent with the NSCLC phenotype in an N-myc amplified SCLC cell line, ...SCLC-specific growth requirement for gastrin-releasing peptide, and inducing mRNA expression of three ...
7